[2] Sabine Schnyder Ghamloush, et al. Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an Investigational Respiratory Syncytial Virus Vaccine, in Participants Aged 2 to < 18 Years at High Risk of Severe Disease. IDWeek 2024; ...
3.Cnossen VM, et al. From setbacks to success: lessons from the journey of RSV vaccine development. Ther Adv Vaccines Immunother. 2024 Dec 19;12:25151355241308305. 4.Gong X, et al. Clinical research on RSV prevention in children and pregnant women: progress and perspectives. Front Immunol. 2...
[2] Sabine Schnyder Ghamloush, et al. Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an Investigational Respiratory Syncytial Virus Vaccine, in Participants Aged 2 to < 18 Years at High Risk of Severe Disease. IDWeek 2024; Abstract 168. 来源:《感染医线》 声明 凡署名原创的文章版权...
1，J Tregoning, et al., RSV vaccines: a new hope but the virus might strike back. Vaccine Insights 2024; 3(1), 47-64.2，You Li, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger th...
呼吸道合胞病毒RSV疫苗抗原最优解：融合前构象（Pre-F）RSV疫苗前沿速递 2024年6月7日，葛兰素史克（GSK）宣布Arexvy适用范围扩展至50-59岁的RSV高危成人。Arexvy包含RSV融合前重组pre-F糖蛋白及AS01E佐剂，是首款FDA批准的RSV疫苗。2024年8月14日，辉瑞（Pfizer）宣布在免疫功能低下的成年患者中，接种两剂...
Novavax RSV Vaccine Pipeline NIAID: VRC-317 (DS-Cav1) 在进行基于 RSV F 蛋白融合前构象开发的疫苗产品前,不得不提到“DS-Cav1”,也就是 NIAID 团队开发的第一个融合前构象的 RSV F 蛋白疫苗设计,并在临床上进行了概念验证。具体设计就不多说了。 VRC-317 (DS-Cav1)疫苗在临床 I 期概念验证中,展示...
1%。最常见的不良反应是注射部位疼痛、疲劳、头痛、肌痛、关节痛、腋窝肿胀或压痛和发冷。参考来源：‘Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)’，新闻稿。Moderna, Inc.；2024年5月31日发布。注：本文旨在介绍医药健康研究，不作任何用药依据，具体用药指导，请咨询主治医师。
Novavax RSV Vaccine Pipeline NIAID: VRC-317 (DS-Cav1)在进行基于 RSV F 蛋白融合前构象开发的疫苗...
[2] US FDA approves expanded age indication for GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk. Retrieved June 10, 2024, from https://www.gsk.com/en-gb/media/press-releases/us-fda-approves-expanded-age-indication-for-gsk-s-ar...
原文:J Tregoning, H Li, C Thomas et al., RSV vaccines: a new hope but the virus might strike back. Vaccine Insights 2024; 3(1), 47–64. 识别微信二维码,添加生物制品圈小编,符合条件者即可加入 生物制品微信群! 请注明:姓名+研究方向!